Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures

  title={Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures},
  author={Frank M. C. Besag and Philip N Patsalos},
  journal={Neuropsychiatric Disease and Treatment},
  pages={1215 - 1220}
Background and purpose Perampanel, a selective noncompetitive antagonist at the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is highly effective in a wide range of experimental models. Although initially licensed as adjunctive therapy for partial seizures with or without secondary generalization in patients aged 12 years or older, the US Food and Drug Administration has recently approved its use in the treatment of primary generalized tonic–clonic seizures (PGTCS). This… Expand
Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations
Results of an objective seizure response in 9 (75%) out of 12 patients treated by PER in DRE may be interpreted as a surrogate-marker of tumor response secondary to AMPA blockade, advancing confirmation by MR imaging. Expand
Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy
Adjunctive perampanel demonstrated a favourable safety profile and long-term tolerability in Japanese patients with refractory partial-onset seizures for ≤316 weeks. Expand
Safety aspects of antiepileptic drugs—a population-based study of adverse effects relative to changes in utilisation
This study demonstrates that most adverse effects reported concerned AEDs increasingly used in non-epilepsy indications: neuropathic pain (pregabalin, gabapentin, carbamazepine) and psychiatry (lamotrigine, valproate, carbazepine). Expand
It is concluded that perampanel is a promising drug in treating epilepsy (even in epilepsies resistant to many other AEDs) with favorable indicators of tolerability. Expand
High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology
An in vivo drug screening strategy that combines high-throughput technology to generate large-scale brain activity maps to be used with machine learning to predict the therapeutic potential of clinically relevant drug leads is described. Expand
Features of psychological reactions induced by perampanel: A case report
Perampanel, an anticonvulsant, might induce psychological reactions and be used in clinical practice to treat central nervous system disorders. Expand


Adjunctive perampanel for refractory partial-onset seizures
This trial demonstrated that once-daily, adjunctive perampanel at doses of 8 or 12 mg improved seizure control in patients with uncontrolled partial-onset seizures. Expand
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy
This study provides Class I evidence that adjunctive perampanel reduces PGTC seizure frequency, compared with placebo, in patients with drug-resistant PGTC seizures in IGE. Expand
Clinical experience with perampanel: Focus on psychiatric adverse effects
In the authors' experience, PER had a retention rate of 55% and a responder rate of 28%. Expand
The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist
Overall, perampanel has a favorable clinical pharmacology profile, which should aid its clinical use and can be used to advantage because dose titration can be faster and thus optimum therapeutic outcome can be achieved sooner. Expand
Adverse effects and safety profile of perampanel: A review of pooled data
Overall, perampanel appears to be associated with a relatively low incidence of serious adverse effects, particularly at low doses, and the majority of TEAEs were mild or moderate in intensity. Expand
Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)☆
Initial evidence is provided that add-on treatment with perampanel might be highly effective in progressive myoclonic epilepsy such as Lafora disease, and a prospective, multicenter study evaluating perampsanel in PME is suggested. Expand
Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel
Perampanel treatment during the extension study reduced total seizure frequency/28 days relative to the double-blind prerandomization baseline regardless of prior perampsanel or placebo treatment in the core studies. Expand
Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.
Perampanel seems to be effective also in children and adolescents with pharmaco-refractory epilepsies and tolerability was acceptable. Expand
A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus
The concentrations of perampanel required to reduce AMPA receptor-mediated responses are not dissimilar to those in plasma following anti-convulsant doses and are consistent with AMPA receptors antagonism being its primary mode of action. Expand
Randomized phase III study 306
This trial demonstrated that adjunctive perampanel effectively reduced seizure frequency and possessed a favorable tolerability profile in patients ≥12 years with partial-onset seizures (with or without secondary generalization), with a minimum effective dose of 4 mg/day. Expand